hereditary haemorrhagic telangiectasia

News

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

News

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.